The　early　history　of　retinal　laser　therapy　began　with　the　observation　of　solar　blindness,　leading　to　the　development　of　various　laser　technologies　for　treating　retinal　diseases.　The　first　retinal　photocoagulation　machine　was　developed　in　1956,　and　subsequent　advancements　introduced　ruby　and　argon　lasers.　While　conventional　theories　posited　that　retinal　damage　was　an　indispensable　prerequisite　for　therapeutic　effects,　emergent　insights　highlight　the　non-damaging　mechanisms,　such　as　photostimulation-　and　self-repair-related　mechanisms.　Novel　therapies,　such　as　subthreshold　micropulse　laser　(SMPL)　and　selective　retina　therapy　(SRT),　are　now　being　employed　alongside　innovative　delivery　systems　to　improve　treatment　efficiency　and　safety.　Clinical　studies　are　underway　to　evaluate　the　efficacy　of　these　therapies　for　conditions　like　diabetic　retinopathy　and　central　serous　chorioretinopathy.　Despite　the　challenges　in　standardization　and　long-term　evaluation,　these　innovations　represent　significant　progress　towards　safer　and　more　effective　laser　treatment　for　retinal　diseases.